Previously declined oncology target
UK / US·SV Biotech
SV reviewed this target in February 2025 and elected not to pursue it. Accumulated independent validation, IP activity and a pharma programme now challenge two assumptions underlying that decision.
Why now?
The evidence underlying SV’s original February 2025 decision has materially changed.
How this came into view
Timeline
2 days ago
Second independent validation published.
3 weeks ago
Pharma programme against the target disclosed.
2 months ago
Third patent family in the space filed.
4 months ago
New academic collaboration formed around the target.
What this judgement rests on
Evidence map
Every strand is classified by where it came from. Select a strand to see the underlying evidence and how much weight it can honestly bear.
Evidence map
Previously declined oncology target
No single item created this opportunity. Select a dimension to inspect the underlying evidence.
Prior SV decision
SVFebruary 2025 — do not pursue · Recorded
Underlying evidence
- Investment review note (Feb 2025)
- Recorded reasoning: insufficient validation
This is an illustrative intelligence object built on representative data. Atlas prepares the judgement; an SV partner decides. Nothing here is an automated action.